BioAsset

Insights / All articles

Company Analysis

The Parkinson’s Bet That Couldn’t Hold $15: Aspen Neuroscience’s IPO

By Judy Dalati, Research Analyst at BioAsset · 5 slides

Aspen Neuroscience’s IPO landed in the hottest biotech market since 2021. Within two weeks, it was trading about 17% below its IPO price.

Skin cells to brain cells

Aspen Neuroscience is developing a one-time Parkinson’s treatment that replaces the dopamine neurons the disease destroys, using a patient’s own skin cells. Today’s drugs, like levodopa, control symptoms but don’t replace lost neurons or slow the disease.

Aspen takes a skin sample, reprograms the cells into stem cells, then turns those into dopamine neurons that mature once placed back in the patient. Because the cells are the patient’s own, the body shouldn’t reject them.

An IPO on markdown

Aspen marketed its shares at $15-$17, then priced at $15, the low end, raising $140.6M. It closed its first day at $14.89, then fell another 12% to $13.04 on Nov. 2. By Nov. 9, it was trading at about $12.40, roughly 17% below the IPO price.

The timing made it stranger. Twenty-nine biotechs have gone public in the U.S. this year, the most since 2021. Investors are clearly buying biotech again, just not this one at full price.

The data problem

The early results look strong. At 12 months, patients gained about two more hours of well-controlled symptoms a day, and motor scores improved by 13.5-15.5 points with no severe dyskinesia. But those results are from the first eight patients, in an open-label trial with no control group. Parkinson’s responds strongly to placebo, so it’s hard to separate the cells’ effect from expectation.

History serves as a warning. In the 1990s, fetal cell transplants also looked promising in uncontrolled studies. Once tested against sham surgery (fake surgery used as a placebo), the transplants showed no overall benefit, and in 2003, 56% of patients developed uncontrolled movements that persisted even off medication. Aspen’s lab-grown cells are a different technology, but investors haven’t seen them beat a control group yet.

$488M in, $361M out

Aspen raised about $347M privately before its IPO, plus $140.6M in the offering, roughly $488M in total. By Nov. 9, it was valued at about $361M, and about $213M of that was cash ($72.4M at the end of June plus the IPO proceeds). The market was paying only about $150M for the pipeline itself.

Aspen has no revenue and lost $36.5M in the first half of 2026, a pace of roughly $73M a year. That means it had only about one year of cash left before the IPO. Aspen says its cash will last into the second half of 2028, about a year after its Phase 3 trial starts in the second half of 2027. We expect another raise, and dilution for shareholders, before the Phase 3 data arrive. That’s our estimate.

The therapy is also hard to scale. Each dose is made from one patient’s own cells, so there’s no mass production. That makes it slow and costly to scale, even if it ends up working.

The verdict

Seventeen biotechs raised at least $250M in IPOs this year, but cell and gene therapy companies haven’t drawn the same interest. Aspen’s $140.6M was $109M short of that mark. Scribe, the only other genetic medicine company to go public this year, raised about $129M. Same-day peer Bambusa, an antibody company that raised $168.9M, also dipped on its debut but was back near its $16 IPO price within days. Aspen is still about 17% below its $15 IPO price.

There is a competitor ahead of it, too. Bayer’s BlueRock already has its Parkinson’s cell therapy in Phase 3. BlueRock uses donor cells, which are easier to mass-produce. Aspen bets its approach is safer because it avoids a long course of immunosuppressants. It’s safety vs. scale.

What to watch: Aspen plans to start Phase 3 before its long-term data arrive in 2028. Whether that trial includes a control group will show whether the science holds up and whether Aspen can become a business. The science might work. Now it has to beat a placebo and BlueRock.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.